NEW YORK, March 25 - Agencourt Bioscience on Monday said that the Duke University Medical Center has picked its Solid Phase Reversible Immobilization technology to help its cancer research.
The deal, funded by the National Cancer Institute's Cancer Genome Anatomy Project, will give researchers at Duke's Brain Cancer Genomics Laboratory access to Agencourt's SPRI technology to help them determine the molecular anatomy of normal, pre-cancer, and cancer cells. Terms also call for Agencourt to sequence Duke's SAGE libraries.
Financial details of the deal were not disclosed, though both groups said that all resources generated by the project will be publicly available.
"Mapping, evaluating, and sequencing the genes of cells at various stages of cancer growth will eventually lead to improved detection, diagnosis and treatment for cancer patients," Agencourt said in a statement.